Applications of 1-O-Acetyl-2,3,5-Tri-O-Benzoyl-Beta-D-Ribofuranose in Industrial Manufacturing

Our expertise in synthesizing 1-O-Acetyl-2,3,5-Tri-O-Benzoyl-Beta-D-Ribofuranose supports a concentrated range of specialized downstream manufacturing fields, where this protected ribofuranose derivative functions as a critical building block for advanced nucleotide and nucleoside compounds. Below, we detail practical industrial application scenarios where strict compliance, defined dosage ranges, controlled integration points, and specific end products are essential for success.

1. Active Pharmaceutical Ingredient (API) Synthesis: Nucleoside Analog Intermediates

Leading pharmaceutical manufacturers incorporate this ribofuranose derivative as a protected sugar intermediate in multi-step syntheses of nucleoside analogs for antiviral, anticancer, and antifungal APIs. The specific benzoyl- and acetyl-protected configuration ensures precise glycosylation, minimizing side reactions and enabling consistent batch-to-batch purity in regulated large-scale API production environments.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 210/211 (cGMP for drug products)
• EU GMP (EudraLex Volume 4)
• Japanese Pharmacopoeia (JP) & European Pharmacopoeia (EP) purity standards for intermediates

Typical usage ratio

• 0.8–1.2 molar equivalents relative to nucleobase substrate, adjusted based on nucleoside analog design and process scale

Downstream process integration

• Engages at glycosylation step, following nucleobase preparation, using Lewis or Brønsted acid catalysis in polar aprotic solvents; selective deprotection yields free nucleoside post-coupling

Final product types

• Antiviral drugs such as sofosbuvir intermediates
• Oncology nucleoside analogs (e.g., clofarabine, cytarabine)
• Antifungal agent intermediates
• Non-clinical research APIs for nucleoside biological probes

2. Oligonucleotide Active Material Foundation

Contract and proprietary oligonucleotide manufacturers utilize this ribofuranose derivative in the preparation of protected ribonucleoside phosphoramidite monomers for RNA oligonucleotide chain assembly. Rigorous protecting groups and purity enable consistent quality in RNA synthesis, crucial for mRNA therapeutics, diagnostic probes, and gene editing reagents where residual impurities can interfere with target specificity.

Industry compliance standards

• ISO 13485 for medical device oligonucleotides
• USP <1049> Analytical Procedures for Oligonucleotides
• QSR 21 CFR Part 820 for in vitro diagnostic components
• Internal quality protocols for biopharma oligo production

Typical usage ratio

• 1.0 equivalent per protected nucleobase or uracil/thymine analog; formulation adjusted for target phosphoramidite batch molecular weight

Downstream process integration

• Chemical glycosylation of nucleobase with protected ribofuranose precursor, followed by selective deprotection and phosphitylation; integration before solid-phase oligonucleotide assembly

Final product types

• Custom or therapeutic mRNA oligonucleotides
• siRNA and antisense RNA agents
• Molecular diagnostic probe reagents (PCR, qPCR)
• Gene editing oligonucleotide scaffolds

3. Veterinary Drug Raw Materials Manufacturing

Large-scale veterinary pharmaceutical plants rely on benzoyl-protected ribofuranose for the targeted synthesis of nucleoside-based antiviral and antiparasitic raw materials formulated for animal health. Process consistency enables compliance with region-specific veterinary pharmaceutical standards, where strict residue controls and known impurity profiles are mandatory for feed additive and injectable product registrations.

Industry compliance standards

• VICH GL3 Good Manufacturing Practice for Veterinary Drugs
• China Veterinary Pharmacopoeia (CVP) specifications
• EU Regulation (EC) No 470/2009 (veterinary medicine MRLs)
• US FDA Guidance for Industry: Veterinary Drug Residue

Typical usage ratio

• 1.0–1.1 equivalents per nucleobase used in prodrug intermediate synthesis; fine-tuned for target veterinary API purity and conversion yield

Downstream process integration

• Enters as ribose donor during protected nucleoside intermediate stage, followed by gradual deprotection, crystallization, and formulation step for veterinary pharmaceutical ingredient

Final product types

• Veterinary antiviral medication intermediates
• Antiparasitic nucleoside derivatives
• Feed additive nucleoside analogs
• Bulk ingredients for injectable veterinary drugs

4. Research and Diagnostic Biochemical Reagent Production

Laboratory and industrial producers of research-grade nucleoside standards and biochemical test reagents employ this ribofuranose derivative to access protected ribonucleoside structures. The defined structure and high-purity profile provide reliable performance in downstream deprotection and derivatization protocols, critical for reproducibility in diagnostic and analytical settings.

Industry compliance standards

• ISO 9001:2015 Quality Management for laboratory reagents
• ISO/IEC 17025:2017 Testing Competence (analytical reference standards)
• Chemical reagent purity standards (ACS, analytical grade)
• OECD GLP (Good Laboratory Practice) guidelines for chemical production

Typical usage ratio

• Generally 1.0 molar equivalent per nucleobase reactant; can vary ±10% to optimize downstream derivatization based on research or diagnostic assay design

Downstream process integration

• Acts as the ribose moiety source during nucleoside synthesis within protected sugar-nucleobase coupling, followed by site-specific deprotection; subsequent steps allow for custom reagent or labelled standard generation

Final product types

• Nucleoside reference standards for HPLC and LC-MS calibration
• Enzyme substrates for nucleoside/kinase assays
• Diagnostic kit nucleoside components
• Synthetic building blocks for chemical biology research